Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle

Samuel F Bakhoum; Charles M Rudin

doi:10.1016/j.xcrm.2021.100406

Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle

Cell Rep Med. 2021 Sep 23;2(9):100406. doi: 10.1016/j.xcrm.2021.100406. eCollection 2021 Sep 21.

Authors

Samuel F Bakhoum^{1

2}, Charles M Rudin^{3

4}

Affiliations

¹ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Abstract

In the current issue of Cancer Cell, Lan et al.¹ demonstrate that a bifunctional fusion protein targeting TGF-β and PD-L1 can synergize with radiation therapy to simultaneously augment tumor control and reduce normal tissue toxicity.

Publication types

Comment

MeSH terms

B7-H1 Antigen*
Humans
Neoplasms* / radiotherapy
Transforming Growth Factor beta

Substances

B7-H1 Antigen
Transforming Growth Factor beta

Abstract

Publication types

MeSH terms

Substances

Grants and funding